A CCL5 Haplotype Is Associated with Low Seropositivity Rate of HCV Infection in People Who Inject Drugs

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2016 Jun 16

PMID 27304910

Citations 2

Authors

Kristi Huik

Radko Avi

Merit Pauskar

Eveli Kallas

Ene-Ly Jogeda

Tonis Karki

Kristi Ruutel

Ave Talu

Katri Abel-Ollo

Anneli Uuskula

Andrew Carrillo

Sunil K Ahuja

Weijing He

Irja Lutsar

Affiliations

Soon will be listed here.

Abstract

Objective: The role of CC chemokine receptor 5 (CCR5) and its ligand CCL5 on the pathogenesis of HIV infection has been well studied but not for HCV infection. Here, we investigated whether CCL5 haplotypes influence HIV and HCV seropositivity among 373 Caucasian people who inject drugs (PWID) from Estonia.

Methods: Study included 373 PWID; 56% were HIV seropositive, 44% HCV seropositive and 47% co-infected. Four CCL5 haplotypes (A-D) were derived from three CCL5 polymorphisms (rs2107538/rs2280788/rs2280789) typed by Taqman allelic discrimination assays. The data of CCR5 haplotypes were used from our previous study. The association between CCL5 haplotypes with HIV and/or HCV seropositivity was determined using logistic regression analysis.

Results: Possessing CCL5 haplotype D (defined by rs2107538A/rs2280788G/rs2280789C) decreased the odds of HCV seropositivity compared to those not possessing it (OR = 0.19; 95% CI 0.09-0.40), which remained significant after adjustment to co-variates (OR = 0.08; 95% CI 0.02-0.29). An association of this haplotype with HIV seropositivity was not found. In step-wise logistic regression with backward elimination CCL5 haplotype D and CCR5 HHG*1 had reduced odds for HCV seropositivity (OR = 0.28 95% CI 0.09-0.92; OR = 0.23 95% CI 0.08-0.68, respectively) compared to those who did not possess these haplotypes, respectively.

Conclusions: Our results suggest that among PWID CCL5 haplotype D and CCR5 HHG*1 independently protects against HCV. Our findings highlight the importance of CCL5 genetic variability and CCL5-CCR5 axis on the susceptibility to HCV.

Citing Articles

mTOR Signaling Pathway Regulates the Release of Proinflammatory Molecule CCL5 Implicated in the Pathogenesis of Autism Spectrum Disorder.

Wang B, Qin Y, Wu Q, Li X, Xie D, Zhao Z Front Immunol. 2022; 13:818518.

PMID: 35422816 PMC: 9002353. DOI: 10.3389/fimmu.2022.818518.

Significance of CCL2, CCL5 and CCR2 polymorphisms for adverse prognosis of Japanese encephalitis from an endemic population of India.

Chowdhury P, Khan S Sci Rep. 2017; 7(1):13716.

PMID: 29057937 PMC: 5651904. DOI: 10.1038/s41598-017-14091-8.

References

Galvin S, Cohen M . The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol. 2004; 2(1):33-42. DOI: 10.1038/nrmicro794. View

Huik K, Sadam M, Karki T, Avi R, Krispin T, Paap P . CCL3L1 copy number is a strong genetic determinant of HIV seropositivity in Caucasian intravenous drug users. J Infect Dis. 2010; 201(5):730-9. PMC: 2836481. DOI: 10.1086/650491. View

Lechner F, Wong D, Dunbar P, Chapman R, Chung R, Dohrenwend P . Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med. 2000; 191(9):1499-512. PMC: 2213430. DOI: 10.1084/jem.191.9.1499. View

Kusano F, Tanaka Y, Marumo F, Sato C . Expression of C-C chemokines is associated with portal and periportal inflammation in the liver of patients with chronic hepatitis C. Lab Invest. 2000; 80(3):415-22. DOI: 10.1038/labinvest.3780046. View

Abad-Molina C, Garcia-Lozano J, Montes-Cano M, Torres-Cornejo A, Torrecillas F, Aguilar-Reina J . HAVCR1 gene haplotypes and infection by different viral hepatitis C virus genotypes. Clin Vaccine Immunol. 2011; 19(2):223-7. PMC: 3272938. DOI: 10.1128/CVI.05305-11. View

Wasmuth H, Werth A, Mueller T, Berg T, Dietrich C, Geier A . Haplotype-tagging RANTES gene variants influence response to antiviral therapy in chronic hepatitis C. Hepatology. 2004; 40(2):327-34. DOI: 10.1002/hep.20322. View

Paxton W, Martin S, Tse D, OBrien T, Skurnick J, VanDevanter N . Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nat Med. 1996; 2(4):412-7. DOI: 10.1038/nm0496-412. View

Tallo T, Norder H, Tefanova V, Krispin T, Schmidt J, Ilmoja M . Genetic characterization of hepatitis C virus strains in Estonia: fluctuations in the predominating subtype with time. J Med Virol. 2007; 79(4):374-82. DOI: 10.1002/jmv.20828. View

Shields P, Morland C, Salmon M, Qin S, Hubscher S, Adams D . Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. J Immunol. 1999; 163(11):6236-43. View

10.

Thomas D, Thio C, Martin M, Qi Y, Ge D, OhUigin C . Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009; 461(7265):798-801. PMC: 3172006. DOI: 10.1038/nature08463. View

11.

Huik K, Avi R, Carrillo A, Harper N, Pauskar M, Sadam M . CCR5 haplotypes influence HCV serostatus in Caucasian intravenous drug users. PLoS One. 2013; 8(7):e70561. PMC: 3723663. DOI: 10.1371/journal.pone.0070561. View

12.

Matloubian M, Concepcion R, Ahmed R . CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol. 1994; 68(12):8056-63. PMC: 237269. DOI: 10.1128/JVI.68.12.8056-8063.1994. View

13.

Raport C, Gosling J, Schweickart V, Gray P, Charo I . Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1beta, and MIP-1alpha. J Biol Chem. 1996; 271(29):17161-6. DOI: 10.1074/jbc.271.29.17161. View

14.

Broadhead R, van Hulst Y, Heckathorn D . The impact of a needle exchange's closure. Public Health Rep. 1999; 114(5):439-47. PMC: 1308516. DOI: 10.1093/phr/114.5.439. View

15.

Grakoui A, Shoukry N, Woollard D, Han J, Hanson H, Ghrayeb J . HCV persistence and immune evasion in the absence of memory T cell help. Science. 2003; 302(5645):659-62. DOI: 10.1126/science.1088774. View

16.

Furci L, Scarlatti G, Burastero S, Tambussi G, Colognesi C, Quillent C . Antigen-driven C-C chemokine-mediated HIV-1 suppression by CD4(+) T cells from exposed uninfected individuals expressing the wild-type CCR-5 allele. J Exp Med. 1997; 186(3):455-60. PMC: 2198997. DOI: 10.1084/jem.186.3.455. View

17.

Jansson M, Popovic M, Karlsson A, Cocchi F, Rossi P, Albert J . Sensitivity to inhibition by beta-chemokines correlates with biological phenotypes of primary HIV-1 isolates. Proc Natl Acad Sci U S A. 1996; 93(26):15382-7. PMC: 26413. DOI: 10.1073/pnas.93.26.15382. View

18.

Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N . Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009; 41(10):1105-9. DOI: 10.1038/ng.449. View

19.

Nattermann J, Nischalke H, Feldmann G, Ahlenstiel G, Sauerbruch T, Spengler U . Binding of HCV E2 to CD81 induces RANTES secretion and internalization of CC chemokine receptor 5. J Viral Hepat. 2004; 11(6):519-26. DOI: 10.1111/j.1365-2893.2004.00545.x. View

20.

Solari R, Offord R, Remy S, Aubry J, Wells T, Whitehorn E . Receptor-mediated endocytosis of CC-chemokines. J Biol Chem. 1997; 272(15):9617-20. DOI: 10.1074/jbc.272.15.9617. View